Adults with relapsed acute lymphoblastic leukemia (ALL) have a poor prognosis, especially in patients who relapsed within 6 months of complete remission 1 (CR1). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the treatment of choice. | CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute Blymphoblastic leukemia A case report